Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

Abstract

Liraglutide reduces metabolic dysfunction, insulin resistance and lipotoxicity in the key metabolic organs in the pathogenesis of NASH. Liraglutide may offer the potential for a disease-modifying intervention in NASH.